Skip to content

Comparative study of transurethral endoscopic submucosal dissection and resection of the bladder tumor for Non-Muscle-Invasive Bladder Cancer

Comparative study of transurethral endoscopic submucosal dissection and resection of the bladder tumor for Non-Muscle-Invasive Bladder Cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-ICR-15006571
Enrollment
Unknown
Registered
2015-06-14
Start date
2015-06-03
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bladder cancer

Interventions

A:TURBT
B:endoscopic submucosal dissection

Sponsors

Shaanxi Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Non-Muscle-Invasive Bladder Cancer approved by CT and Cystoscope; 2. The diameterof tumor is greater than 0.5cm; 3. age between 18-80 years, male or female; 4. patients signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Age < 18 years old; 2. Muscle-Invasive Bladder Cancer; 3. Pregnant woman; 4. patients is not sign the informed consent; 5. Multiple lesions, more than 5 independent focus; 6. The tumor could not be completely removed; 7. The tumor is large so that endoscopic view can not operate; 8. contracted bladder; 9. Spacious CIS which cannot be completely removed endoscopically; 10. with complication of other tumors or systemic diseases, such as severe coagulopathy, uncontrolled psychosomatic disease.

Design outcomes

Primary

MeasureTime frame
Recurrence of tumor;

Secondary

MeasureTime frame
time of opration;time of bladder irrigation;time of catheter indwelling;time of hospital stay;The R0 resection rate;Percentage of tumour-free Re-TUR;

Countries

China

Contacts

Public ContactCheng Yongyi
chengyy100@126.com+86 13309292900

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026